Content area
Abstract
The incidence of diabetes is increasing, but that of diabetic retinopathy is falling, probably owing to better management of glucose levels, lipid abnormalities, and hypertension. Clinical trials of VEGF and PPAR-α inhibitors are improving vision and providing insights into pathogenesis.
Details
Title
Diabetic Retinopathy
Author
Antonetti, David A; Klein, Ronald; Gardner, Thomas W 1
1 From the Departments of Ophthalmology and Visual Sciences and Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor (D.A.A., T.W.G.); and the Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison (R.K.).
1 From the Departments of Ophthalmology and Visual Sciences and Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor (D.A.A., T.W.G.); and the Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison (R.K.).
Pages
1227-1239
Section
Review Article
Publication year
2012
Publication date
Mar 29, 2012
Website
ISSN
00284793
e-ISSN
15334406
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
963505264
Copyright
Copyright © 2012 Massachusetts Medical Society. All rights reserved.